0.7399

15.87% -0.1396

After Hours: .78 0.0401 +5.42%

Calidi Biotherapeutics Inc (CLDI)

Overview News Price History Discussions Forecast

Calidi Biotherapeutics Inc stock is traded at $0.7399, with a volume of 787.01K. It is down -15.87% in the last 24 hours and down -29.53% over the past month. Calidi Biotherapeutics Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is headquartered in San Diego, California.

Previous Close:

$0.8795

Open:

$0.8542

24h Volume:

787.01K

Relative Volume:

0.50

Market Cap:

$19.17M

Revenue:

Net Income/Loss:

$-23.36M

P/E Ratio:

-1.0042

EPS:

-0.7368

Net Cash Flow:

1W Performance:

-23.80%

1M Performance:

-29.53%

6M Performance:

-33.94%

1Y Performance:

-88.21%

1-Day Range:

$0.7126

$0.90

1-Week Range:

$0.7126

$0.9899

52-Week Range:

$0.58

$8.30

Calidi Biotherapeutics Inc Stock (CLDI) Company Profile

Name

Calidi Biotherapeutics Inc

Sector

Healthcare (1170)

Industry

Biotechnology (682)

Phone

(858) 794-9600

Address

4475 Executive Drive, Suite 200, San Diego

Employee

Twitter

Next Earnings Date

Latest SEC Filings

CLDI's Discussions on Twitter

Compare CLDI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CLDI Calidi Biotherapeutics Inc	0.7399	19.17M	0	-23.36M	0	-0.7368
VRTX Vertex Pharmaceuticals Inc	483.31	124.11B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	684.87	74.87B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	622.61	37.83B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	243.53	31.53B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	111.56	26.75B	3.30B	-501.07M	1.03B	-2.1146

Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-22-23	Initiated	H.C. Wainwright	Buy
Oct-09-23	Initiated	Robert W. Baird	Outperform

Calidi Biotherapeutics Inc Stock (CLDI) Latest News

Feb 28, 2025

Calidi Biotherapeutics prices $7.5M secondary offering - MSN

Feb 28, 2025

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - WSIL TV

Feb 28, 2025

Calidi Biotherapeutics to Showcase Cancer-Fighting Oncolytic Virus Platform on Bloomberg TV | OSTX Stock News - StockTitan

Feb 28, 2025

Feb 27, 2025

Calidi Biotherapeutics is initiating GMP manufacturing at VetStem BioPharma, a veterinary and human regenerative medicine company in San Diego, CA - ACCESS Newswire

Feb 27, 2025

ASP Isotopes and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire

Feb 27, 2025

Feb 25, 2025

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Drives Growth With Strengthened Financial Position And Cutting-Edge Research - MENAFN.COM

Feb 25, 2025

Feb 24, 2025

Calidi Biotherapeutics Announces Commencement of - GlobeNewswire

Feb 24, 2025

Closing Figures Unveiled: Calidi Biotherapeutics Inc (CLDI) Drop -16.67, Closes at 1.05 - The Dwinnex

Feb 24, 2025

Calidi Biotherapeutics Initiates Recruitment for CLD-101 Clinical Trial Targeting High-Grade Glioma - Nasdaq

Feb 24, 2025

Can Multiple Doses Make This Brain Cancer Treatment More Effective? Northwestern Launches Next-Phase Trial - StockTitan

Feb 24, 2025

Feb 19, 2025